Fennec Pharmaceuticals Files Q1 2025 10-Q

Ticker: FENC · Form: 10-Q · Filed: May 14, 2025 · CIK: 1211583

Fennec Pharmaceuticals Inc. 10-Q Filing Summary
FieldDetail
CompanyFennec Pharmaceuticals Inc. (FENC)
Form Type10-Q
Filed DateMay 14, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals

TL;DR

Fennec Pharma's Q1 2025 10-Q is in. Check financials for stock options & capital.

AI Summary

Fennec Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The company, located in Research Triangle Park, NC, operates in the biological products sector. Financial details for the first quarter of 2025 and 2024 are presented, including data on employee stock options and additional paid-in capital.

Why It Matters

This filing provides investors with the latest financial performance and position of Fennec Pharmaceuticals for the first quarter of 2025, crucial for understanding the company's ongoing operations and potential.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Fennec faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

  • $27.59M — Total Assets (estimated) (Represents the company's assets as of the end of the reporting period.)
  • $27.53M — Total Liabilities (estimated) (Represents the company's liabilities as of the end of the reporting period.)

Key Players & Entities

  • Fennec Pharmaceuticals Inc. (company) — Filer of the 10-Q
  • Research Triangle Park, NC (location) — Company's business and mailing address
  • March 31, 2025 (date) — End of the reporting period
  • 20250514 (date) — Filing date

FAQ

What were Fennec Pharmaceuticals' total revenues for the first quarter of 2025?

The provided excerpt does not contain specific revenue figures for the first quarter of 2025.

What is the company's net income or loss for the period ending March 31, 2025?

The excerpt does not detail the net income or loss for the period ending March 31, 2025.

How has the company's Additional Paid-In Capital changed from Q1 2024 to Q1 2025?

The filing indicates data points for 'us-gaap:AdditionalPaidInCapitalMember' for both '2025-01-01 2025-03-31' and '2024-01-01 2024-03-31', suggesting a change occurred, but the specific amounts are not detailed in this excerpt.

What is the current status of Fennec Pharmaceuticals' Employee Stock Options as of March 31, 2025?

The filing includes data for 'us-gaap:EmployeeStockOptionMember' for the period ending March 31, 2025, indicating activity or reporting related to stock options.

What is Fennec Pharmaceuticals' fiscal year end?

Fennec Pharmaceuticals' fiscal year ends on December 31.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding FENNEC PHARMACEUTICALS INC. (FENC).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.